KemPharm/$ZVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About KemPharm
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Ticker
$ZVRA
Sector
Primary listing
Employees
59
Headquarters
Website
KemPharm Metrics
BasicAdvanced
$598M
-
-$0.08
1.56
-
Price and volume
Market cap
$598M
Beta
1.56
52-week high
$13.16
52-week low
$6.19
Average daily volume
2M
Financial strength
Current ratio
7.85
Quick ratio
7.661
Long term debt to equity
52.675
Total debt to equity
53.123
Interest coverage (TTM)
-7.12%
Profitability
EBITDA (TTM)
-53.848
Gross margin (TTM)
71.96%
Net profit margin (TTM)
4.26%
Operating margin (TTM)
-97.41%
Effective tax rate (TTM)
87.64%
Revenue per employee (TTM)
$1,050,000
Management effectiveness
Return on assets (TTM)
-18.85%
Return on equity (TTM)
3.53%
Valuation
Price to revenue (TTM)
9.024
Price to book
5
Price to tangible book (TTM)
5.56
Price to free cash flow (TTM)
-12.029
Free cash flow yield (TTM)
-8.31%
Free cash flow per share (TTM)
-0.885
Growth
Revenue change (TTM)
161.81%
Earnings per share change (TTM)
-95.44%
3-year revenue growth (CAGR)
84.89%
3-year earnings per share growth (CAGR)
-55.32%
10-year earnings per share growth (CAGR)
-53.96%
What the Analysts think about KemPharm
Analyst ratings (Buy, Hold, Sell) for KemPharm stock.
Bulls say / Bears say
In April 2025, Zevra completed the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million in gross proceeds, providing non-dilutive capital for commercial launches and development.
Q2 2025 net revenue soared to $25.9 million, up from $4.4 million a year earlier, driven by $21.5 million in MIPLYFFA sales, showing strong market demand for its flagship rare disease therapy.
Zevra submitted a Marketing Authorisation Application to the European Medicines Agency for arimoclomol (MIPLYFFA), advancing efforts to expand its Niemann-Pick Disease Type C treatment in Europe.
Zevra recognized a $58.7 million non-cash impairment on OLPRUVA intangible assets and an $11.7 million inventory write-down in Q2 2025, reflecting difficulties in forecasting and market performance.
OLPRUVA lagged in Q2 2025 with just $0.3 million in net revenue and only a single new prescription, causing the stock to fall nearly 20% due to investor concerns about slow uptake.
MIPLYFFA accounted for about 83% of Q2 2025 product revenue, leaving Zevra exposed to concentration risk if uptake of its lead therapy slows.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
KemPharm Financial Performance
Revenues and expenses
KemPharm Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KemPharm stock?
KemPharm (ZVRA) has a market cap of $598M as of October 07, 2025.
What is the P/E ratio for KemPharm stock?
The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of October 07, 2025.
Does KemPharm stock pay dividends?
No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next KemPharm dividend payment date?
KemPharm (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for KemPharm?
KemPharm (ZVRA) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.